Roffman Miller Associates Inc. PA Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Roffman Miller Associates Inc. PA lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 0.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 263,418 shares of the company's stock after purchasing an additional 2,020 shares during the quarter. Johnson & Johnson comprises 2.8% of Roffman Miller Associates Inc. PA's portfolio, making the stock its 14th largest position. Roffman Miller Associates Inc. PA's holdings in Johnson & Johnson were worth $43,685,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. MRP Capital Investments LLC increased its stake in shares of Johnson & Johnson by 4.1% during the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock valued at $237,000 after buying an additional 65 shares during the period. Syverson Strege & Co grew its holdings in Johnson & Johnson by 4.9% during the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after acquiring an additional 65 shares in the last quarter. Sage Mountain Advisors LLC increased its position in Johnson & Johnson by 0.5% during the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock valued at $2,106,000 after purchasing an additional 67 shares during the period. MBA Advisors LLC raised its holdings in shares of Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after purchasing an additional 68 shares in the last quarter. Finally, Sovereign Financial Group Inc. lifted its position in shares of Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after purchasing an additional 69 shares during the period. Institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on JNJ. Bank of America reduced their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 5th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded up $0.28 during mid-day trading on Wednesday, reaching $156.07. The stock had a trading volume of 6,140,694 shares, compared to its average volume of 8,058,336. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The firm has a market cap of $375.52 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 2.36 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The business's fifty day moving average is $153.67 and its 200-day moving average is $154.25.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.33%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.